With improving research and new knowledge finally leading to some new AD drugs, and possibly for those with other CNS diseases, the there is bound to be new pressures of Medicare.
It is a national crisis and will require some big rethinking about how to fund medicare, who will be eligible for its benefits, and how to re-prioritize better medicine for the aged. It is also going to increase scrutiny on drug pricing, drug approvals, and drug endpoints.
If new drugs can help keep patients more healthy and independent, it will enable some important savings in care giving costs which can be overwhelming high for AD, PD and other CNS patients.
An interesting question is how quickly the new drugs will save more in caregiving costs than the drugs cost? I think that eventually drugs may save more than they cost, but probably not at first, as these new drugs add to the medicare burden.
News 
Market Data 
Discover 
AI
